35 Results for "

collagen-induced arthritis model

" in MedChemExpress (MCE) Product Catalog:
Products (35)

35 Results for "collagen-induced arthritis model" in MCE Product Catalog:

57
57 Publications Verification
Cat. No.: HY-123606
CAS No.: 1652629-23-6
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8 + T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions .
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-153808
CAS No.: 9007-81-2
Research Areas:  

Inflammation/Immunology

Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-153808A
Target:  

Bacterial

Research Areas:  

Inflammation/Immunology Cancer

Incomplete Freund's adjuvant (IFA) (Montanide ISA-51) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund. Incomplete Freund's adjuvant (IFA) does not contain inactivated tuberculosis bacilli and consists of petroleum jelly containing lanolin. Incomplete Freund's adjuvant (IFA) induces high antibody titers and long-lasting effector T cell responses with no long-term effects on collagen disease, tumors, or death. Complete Freund's adjuvant (CFA) (HY-153808) is another type of Freund's Adjuvant that stimulates a stronger immune response .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-153321
CAS No.: 2649400-34-8
Purity:  98.67%
Synonyms: NX-5948; BTK-IN-24
Target:  

PROTACs Btk

Research Areas:  

Inflammation/Immunology

Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-151093
CAS No.: 2803768-09-2
Purity:  98.86%
IDO2-IN-1 is an orally active and potent Indoleamine 2,3-dioxygenase 2 (IDO2) inhibitor with an IC50 value of 112 nM. IDO2-IN-1 can be used for inflammatory autoimmunity research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P10086
CAS No.: 1289375-12-7
Synonyms: Human TREM-1(213-221)
TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, IL-6, and M-CSF. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer .
loading...
    loading...
Cat. No.: HY-168625
CAS No.: 3050683-38-7
Synonyms: VAV1 degrader-3
MRT-6160 (Example 185) is an orally active VAV1 molecular glue degrader (DC50: 7 nM). MRT-6160 reduces immune cell activation, immune cell proliferation and the production of various cytokines. MRT-6160 can be used for research of inflammatory or autoimmune disorder. MRT-6160 inhibits disease progression in experimntal autoimmune encephalomyelitis (EAE) mouse model, Collagen-induced arthritis (CIA) mouse model, etc. .
loading...
    loading...
Cat. No.: HY-164894
ABBV-3373 is an anti-TNF antibody-drug conjugate (ADC). ABBV-3373 consists of a fully human TNF antibody Adalimumab (HY-P9908) conjugated to a glucocorticoid receptor agonist (HY-148436). ABBV-3373 can be used for the research of rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-136990
CAS No.: 959754-85-9
Purity:  99.84%
Target:  

p38 MAPK

Research Areas:  

Cancer

GLPG0259 is a ATP-competitive inhibitor of MAPK-activated protein kinase 5 (MK5) with oral activity. GLPG0259 reduces inflammation and bone destruction in a mouse model of collagen-induced arthritis. GLPG0259 also inhibited the metastasis of prostate cancer (PCa) cells .
loading...
    loading...
Cat. No.: HY-155487
CAS No.: 1404380-58-0
JTE-151 is an orally active, selective RORγ antagonist with IC50 values of 20.6 nM, 41.8 nM and 32.2 nM against hRORγ, rRORγ and mRORγ, respectively . JTE-151 reduces the production of IL-17. JTE-151 alleviates paw swelling and bone destruction in arthritis models. JTE-151 can be used in research related to rheumatoid arthritis, collagen-induced arthritis, experimental autoimmune encephalomyelitis, psoriasis, multiple sclerosis and inflammatory bowel disease .
loading...
    loading...
Cat. No.: HY-174455
CAS No.: 3065494-66-5
Research Areas:  

Inflammation/Immunology

APH02174 is an orally effective and selective IRAK4 PROTAC degrader with a DC50 of 4.01 nM in THP-1 cells. APH02174 inhibits LPS (HY-D1056)-induced IL-6 release by degrading IRAK4 and blocking TLR/IL-1R downstream signaling. APH02174 exhibits favorable anti-inflammatory activity in both Imiquimod (HY-B0180)-induced psoriasis-like skin inflammation and collagen-induced arthritis models. APH02174 is useful for research on inflammatory diseases such as psoriasis and rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-122906
CAS No.: 1255303-54-8
Purity:  99.95%
Target:  

c-Fms

Research Areas:  

Inflammation/Immunology

JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis .
loading...
    loading...
Cat. No.: HY-177435
Target:  

FAP

Research Areas:  

Inflammation/Immunology

FAPI-800CW is a near-infrared (NIR) fluorescent-labeled fibroblast activation protein (FAP) inhibitor. FAPI-800CW shows specific uptake in inflamed paws in collagen-induced arthritis (CIA) model mice. FAPI-800CW can be used for in vivo molecular imaging of FAP expression in inflammatory diseases such as rheumatoid arthritis (RA) to monitor joint inflammation and disease activity .
loading...
    loading...
Cat. No.: HY-178012
CAS No.: 2499855-36-4
Target:  

IRAK TNF Receptor

Research Areas:  

Inflammation/Immunology

GLPG4471 is a selective and orally active IRAK4 inhibitor with an IC50 of 1.7 nM. GLPG4471 exhibits potent inhibition of cytokine (TNFα and IFNα) secretion in cellular and whole blood phenotypic assays. GLPG4471 displays significant activity in a mouse model of collagen-induced arthritis. GLPG4471 can be used for the study of arthritis .
loading...
    loading...
Cat. No.: HY-138007
CAS No.: 1414248-06-8
Target:  

ROR PPAR LXR

SR-1903 is an inverse agonist of RORγ and PPARγ (IC50 of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .
loading...
    loading...
Cat. No.: HY-120041
CAS No.: 1388896-07-8
Target:  

IRAK

Research Areas:  

Cancer

ND-2158 is a competitive IRAK4 inhibitor, with the Ki of 1.3 nM. ND-2158 suppresses LPS-induced TNF production in human white blood cells, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. ND-2158 has antitumor activity in vivo .
loading...
    loading...
Cat. No.: HY-117622
CAS No.: 1388894-17-4
Target:  

IRAK

Research Areas:  

Inflammation/Immunology Cancer

ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models .
loading...
    loading...
Cat. No.: HY-120050
CAS No.: 1621517-53-0
Target:  

Phospholipase

Research Areas:  

Inflammation/Immunology

GK470 (compound 28) is an inhibitor of group IVA cytosolic phospholipase A2 (GIVA cPLA2) with an IC50 of 300 nM in vesicle assays. GK470 has anti-inflammatory activity, inhibiting the release of arachidonic acid in SW982 fibroblast-like synoviocytes with an IC50 value of 0.6 μM. GK470 exhibits comparable anti-inflammatory effects to Methotrexate (HY-14519) in a preventive collagen-induced arthritis model and significantly reduces plasma PGE2 levels .
loading...
    loading...
Cat. No.: HY-155031
MCI alleviates inflammation by macrophage reprogramming via targeting ROS scavenging and COX-2 downregulation. MCI inhibits COX-2 with an IC50 value of 1.23 μM. MCI has significant anti-inflammatory effects in collagen-induced arthritis (CIA) models. MCI can be used in research for rheumatoid arthritis (RA) .
loading...
    loading...
Cat. No.: HY-153321A
CAS No.: 2649400-33-7
Synonyms: (R,R)-NX-5948; (R,R)-BTK-IN-24
Target:  

Drug Isomer PROTACs Btk

Research Areas:  

Inflammation/Immunology Cancer

(R,R)-Bexobrutideg is the (R,R)-enantiomer of Bexobrutideg (HY-153321). Bexobrutideg (NX-5948) is an orally active PROTAC that induces specific BTK protein degradation via a cereblon E3 ligase (CRBN) complex without degrading other cereblon neo substrates. Bexobrutideg mediates potent anti-inflammatory activity through BTK degradation, thereby inhibiting B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models containing wild-type BTK or BTKi resistance mutations. Bexobrutideg is effective in a mouse model of collagen-induced arthritis (CIA). Bexobrutideg can cross the blood-brain barrier. NX-5948 consists of a target protein ligand, a linker, and a VHL E3 ubiquitin ligase (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker) .
loading...
    loading...